These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24549714)

  • 41. Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP.
    Hou Y; Ernst SA; Heidenreich K; Williams JA
    Am J Physiol Gastrointest Liver Physiol; 2016 Jan; 310(1):G26-33. PubMed ID: 26542397
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion.
    Hui H; Yu R; Bousquet C; Perfetti R
    Endocrinology; 2002 Sep; 143(9):3529-39. PubMed ID: 12193567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris.
    Gao Z; Bai G; Chen J; Zhang Q; Pan P; Bai F; Geng P
    Biosci Biotechnol Biochem; 2009 Mar; 73(3):688-94. PubMed ID: 19270384
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL.
    Li R; Yang H; Jia D; Nie Q; Cai H; Fan Q; Wan L; Li L; Lu X
    J Control Release; 2016 Apr; 228():96-106. PubMed ID: 26951928
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucagon-like peptide-1 stimulates insulin secretion by a Ca2+-independent mechanism in Zucker diabetic fatty rat islets of Langerhans.
    Sreenan SK; Mittal AA; Dralyuk F; Pugh WL; Polonsky KS; Roe MW
    Metabolism; 2000 Dec; 49(12):1579-87. PubMed ID: 11145120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers.
    Chae SY; Chun YG; Lee S; Jin CH; Lee ES; Lee KC; Youn YS
    J Pharm Sci; 2009 Apr; 98(4):1556-67. PubMed ID: 18704955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG; Pittner R; Jodka C; Smith P; Young A
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-Term Exposure of Pancreatic β-Cells to Palmitate Results in SREBP-1C-Dependent Decreases in GLP-1 Receptor Signaling via CREB and AKT and Insulin Secretory Response.
    Natalicchio A; Biondi G; Marrano N; Labarbuta R; Tortosa F; Spagnuolo R; D'Oria R; Carchia E; Leonardini A; Cignarelli A; Perrini S; Laviola L; Giorgino F
    Endocrinology; 2016 Jun; 157(6):2243-58. PubMed ID: 27035653
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Small-molecule agonists for the glucagon-like peptide 1 receptor.
    Knudsen LB; Kiel D; Teng M; Behrens C; Bhumralkar D; Kodra JT; Holst JJ; Jeppesen CB; Johnson MD; de Jong JC; Jorgensen AS; Kercher T; Kostrowicki J; Madsen P; Olesen PH; Petersen JS; Poulsen F; Sidelmann UG; Sturis J; Truesdale L; May J; Lau J
    Proc Natl Acad Sci U S A; 2007 Jan; 104(3):937-42. PubMed ID: 17213325
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats.
    Wu L; Olverling A; Huang Z; Jansson L; Chao H; Gao X; Sjöholm Å
    Clin Sci (Lond); 2012 Apr; 122(8):375-84. PubMed ID: 22054347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
    Islam MS; Rahman SA; Mirzaei Z; Islam KB
    Life Sci; 2005 Jan; 76(11):1239-48. PubMed ID: 15642594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L; Frandsen CS; Madsbad S
    Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist.
    Li Y; Zheng X; Yi X; Liu C; Kong D; Zhang J; Gong M
    FASEB J; 2017 Jun; 31(6):2603-2611. PubMed ID: 28270518
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Self-assembling peptides improve the stability of glucagon-like peptide-1 by forming a stable and sustained complex.
    Li Y; Shao M; Zheng X; Kong W; Zhang J; Gong M
    Mol Pharm; 2013 Sep; 10(9):3356-65. PubMed ID: 23859692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and biological evaluation of glucagon-like peptide-1 analogs with the C-terminal helix 3 of albumin-binding domain 3.
    Zhang J; Li S; Dong Y; Tang H; He Y; Hu H; Feng J
    Bioorg Med Chem; 2022 May; 62():116725. PubMed ID: 35358863
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fusion with an albumin-binding domain improves pharmacokinetics of an αvβ3-integrin binding fibronectin scaffold protein.
    Gapizov SS; Petrovskaya LE; Shingarova LN; Kryukova EA; Boldyreva EF; Lukashev EP; Yakimov SA; Svirshchevskaya EV; Dolgikh DA; Kirpichnikov MP
    Biotechnol Appl Biochem; 2019 Jul; 66(4):617-625. PubMed ID: 31140614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of C-terminus Conjugation via Different Conjugation Chemistries on In Vivo Activity of Albumin-Conjugated Recombinant GLP-1.
    Park J; Bak M; Min K; Kim HW; Cho JH; Tae G; Kwon I
    Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33672039
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prolonged half-life of small-sized therapeutic protein using serum albumin-specific protein binder.
    Kim TY; Park JH; Shim HE; Choi DS; Lee DE; Song JJ; Kim HS
    J Control Release; 2019 Dec; 315():31-39. PubMed ID: 31654685
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic Study of SKL-18287, a Novel Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, in Rats, Monkeys and Mini-Pigs.
    Takeuchi M; Okamoto M; Tamura M; Murase T; Watanabe N
    Drug Res (Stuttg); 2019 Sep; 69(9):479-486. PubMed ID: 31083740
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of Strategies for Decreasing Blood Glucose Using Albuminbinding Domain.
    Fan L; Fan Y; Fan H; Huang K
    Curr Pharm Biotechnol; 2020; 21(7):605-612. PubMed ID: 31893990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.